Kairos Pharma, Ltd.
KAPA
$1.66
$0.000.00%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.88% | 30.14% | -31.16% | 124.12% | 503.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.68% | 33.49% | -2.14% | 274.67% | 555.86% |
| Operating Income | 2.68% | -33.49% | 2.14% | -274.67% | -555.86% |
| Income Before Tax | 2.39% | -31.06% | -39.29% | -33.52% | -462.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.39% | -31.06% | -39.29% | -33.52% | -462.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.39% | -31.06% | -39.29% | -33.52% | -462.06% |
| EBIT | 2.68% | -33.49% | 2.14% | -274.67% | -555.86% |
| EBITDA | 1.48% | -34.58% | 2.20% | -306.71% | -678.02% |
| EPS Basic | 21.55% | 1.01% | 10.58% | 27.92% | -244.84% |
| Normalized Basic EPS | 21.51% | 1.01% | 44.49% | 28.00% | -244.85% |
| EPS Diluted | 21.55% | 1.01% | 10.58% | 27.92% | -244.84% |
| Normalized Diluted EPS | 21.51% | 1.01% | 44.49% | 28.00% | -244.85% |
| Average Basic Shares Outstanding | 24.44% | 32.34% | 55.73% | 85.20% | 62.96% |
| Average Diluted Shares Outstanding | 24.44% | 32.34% | 55.73% | 85.20% | 62.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |